Full-Time

Senior Manager

Regulatory Affairs Advertising & Promotion

Posted on 8/23/2025

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

10,001+ employees

Develops biopharmaceutical therapies for serious diseases

Compensation Overview

$148.3k - $241.9k/yr

Tarrytown, NY, USA

In Person

Category
Legal & Compliance (2)
,
Required Skills
Marketing
Requirements
  • A minimum of 3 to 4 years within regulatory affairs, preferably within advertising and promotion
  • At minimum, a Bachelor’s degree (BS) from an accredited College or University in Life Sciences
  • Advanced degree (Masters, Pharm D, Ph.D., MD or DO) preferred in the field of medicine or science
  • Advance knowledge of regulations, guidelines and precedents related to pharmaceutical product development and marketing, with focus in the area of advertising and promotion
  • Experience with pharmaceutical products required, biologics experience is a plus
Responsibilities
  • Management of US and Global (if applicable) regulatory activities associated with advertising and promotion of the company’s marketed products, as well as commercial development of pipeline products
  • Creatively advise on the development of product messages and materials across multiple functional areas
  • Provide timely regulatory advice and guidance, with minimal guidance from Regulatory Affairs, Advertising & Promotion Director, to Commercial teams and Medical Affairs with respect to conference exhibit activities, disease awareness and speaker programs
  • Provide review of US and Global (if applicable) product and disease state materials/communications, with minimal guidance from Regulatory Affairs, Advertising & Promotion Director, to support corporate goals and comply with applicable laws, regulations, and guidance
  • Collaborate cross functionally with key stakeholders in areas such as Marketing, Medical Affairs, and Legal
  • Responsible for establishing working relationship and managing communication with regulatory advertising and promotion professionals at co-promote partner companies
  • Help lead and assist in all interactions with the FDA Office of Prescription drug Promotion (OPDP) for assigned company products, responsible for helping to maintain working relationship and effective communication with FDA OPDP reviewers with respect to advertising and promotion matters, including request for advisory submissions
  • Responsible for compliance with promotional material submissions to FDA on Form 2253
  • Monitor the external environment to advise product teams on evolving regulatory requirements related to product and disease state communications
  • Maintain vigilance with respect to FDA promotional enforcement activities; provide stakeholders with updates on a regular basis; provide guidance to stakeholders with respect to impact of enforcement activities on the company policies
  • Provide input to direct management with respect to process improvement for promotional review activities and establishment of portfolio wide standardization of policies
  • Ability to cross train across products/indications to ensure continuous Regulatory A&P support is provided to stakeholders
  • Collaboration with Regulatory Therapeutic Area Leads to review key marketing application summary documents and study reports
  • With minimal guidance from management, help provide input during review cycles to reflect commercialization objectives and messages in the submission documents/reports that are submitted to health authorities
  • Provide input to management during labeling development and negotiation to reflect commercialization objectives and messages that impact promotion and advertising.
Desired Qualifications
  • Experience working directly/indirectly with the FDA, specifically OPDP/APLB is preferred
  • Ability to review promotional materials and interact with FDA OPDP/APLB and managing launch products/campaigns, while maintaining excellent written/verbal communication skill when giving strategic regulatory advice
  • Ability to support global promotional review, understanding of clinical trial recruitment materials, and familiarity with labeling regulations is desirable
  • Ability to influence cross-functional teams and interact with senior management
Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

View

Regeneron Pharmaceuticals develops and commercializes medicines for serious diseases, with a focus on cancer, eye diseases, allergic and inflammatory diseases, and infectious diseases. Its products come from using proprietary research capabilities and technologies to discover and develop therapies, often in collaboration with academic, research, and industry partners. Revenue comes from selling approved medicines and from licensing its technologies and entering co-development and co-commercialization partnerships. The company works with healthcare providers and regulators to ensure treatment delivery and safety. Its goal is to improve patient outcomes by bringing life-transforming medicines to market through rigorous R&D and strategic collaborations, maintaining leadership in biopharmaceutical innovation.

Company Size

10,001+

Company Stage

IPO

Headquarters

Town of Mount Pleasant, New York

Founded

1988

Simplify Jobs

Simplify's Take

What believers are saying

  • Dupixent global sales surged 33% to $4.9B in Q1 2026, treating 1.4M patients across nine indications.
  • Libtayo net sales grew 54% to $438M in Q1 2026 from CSCC and lung cancer uptake.
  • $27B US R&D and manufacturing commitment secures three-year tariff relief via April 2026 Trump deal.

What critics are saying

  • Biosimilar aflibercept from Viatris erodes legacy EYLEA sales, dropping combined franchise 10% to $941M in Q1 2026.
  • Sanofi renegotiates Dupixent profit-sharing as sales hit $4.9B, cutting Regeneron's 25-50% economics by 2028.
  • Trump most-favored-nation deal mandates Medicaid price cuts on EYLEA and Dupixent, slashing margins 30-50% by mid-2027.

What makes Regeneron Pharmaceuticals unique

  • Proprietary VelociSuite technologies enable rapid homegrown drug discovery across modalities.
  • Developed EYLEA HD with unique 5-month dosing for wet AMD approved by FDA in Q1 2026.
  • Pioneered Otarmeni, first in vivo gene therapy for OTOF-related hearing loss, FDA-approved April 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Wellness Program

Paid Vacation

Equity Awards

Annual Bonuses

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

-3%

1 year growth

-3%

2 year growth

-3%
Endpoints News
Apr 13th, 2026
Regeneron wades into radiopharma through $40M upfront deal with telix.

Regeneron wades into radiopharma through $40M upfront deal with telix. News reporter. Regeneron is set to work on radiopharmaceuticals for the first time in a new partnership to develop solid tumor therapies as... Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. Think Endpoints Company is worth reading - tell google. Confirm Endpoints as a trusted biopharma news source ENDPOINTS CAREERS TCG stealth clinic-ready newco.

AllSci
Apr 13th, 2026
Telix partners with Regeneron on radiopharmaceutical therapies in USD 2.1b potential deal.

Telix partners with Regeneron on radiopharmaceutical therapies in USD 2.1b potential deal. April 13, 2026 Australia-based Telix Pharmaceuticals Ltd (ASX: TLX, Nasdaq: TLX) and US firm Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced a strategic collaboration to jointly develop and commercialize next-generation antibody-based radiopharmaceutical therapies across multiple solid tumor indications. The agreement pairs Telix's radiopharmaceutical development platform and global manufacturing infrastructure with Regeneron's antibody discovery technologies, including its VelocImmune and VelociSuite platforms, to generate a pipeline of radiolabeled biologics. Specific tumor targets have not been disclosed. Deal specifics. Under the deal terms, Telix will receive an upfront payment of USD 40 million from Regeneron for access to its radiopharmaceutical manufacturing platform across four initial therapeutic programs. Should Telix elect to opt out of co-funding on any individual program, it becomes eligible to receive up to USD 535 million in development and commercial milestone payments per program, plus low double-digit royalties on net sales, with an aggregate milestone ceiling of USD 2.1 billion across all programs. Where Telix remains in the co-funding model, the two companies will share equally in global development costs and commercialization profits on a 50/50 basis, with Telix retaining the option to co-promote certain products. The collaboration covers four initial therapeutic programs, with Regeneron holding the option to expand to four additional programs subject to further upfront payments. The parties will also jointly develop radio-diagnostic assets to support patient selection and treatment response monitoring, with Telix leading commercialization of those diagnostics and Regeneron receiving a defined percentage of profits. The exact percentage was not disclosed. The structure gives Telix a per-program election right at a defined decision point: co-fund and share in global profits equally, or opt out and revert to a milestone-plus-royalty economics model. This optionality allows Telix to allocate capital selectively depending on program progression and resource constraints, while preserving upside participation across the portfolio. The agreement is global in scope, with no geographic carve-outs or territorial allocations disclosed. No equity investment by either party in the other was announced in connection with the transaction. The drug programs will combine Regeneron's antibody targeting components, drawn from its portfolio of antibodies generated through VelocImmune mice, with Telix's radiolabeling and manufacturing capabilities. The modality class is antibody-based radiopharmaceutical therapy, in which a tumor-antigen-binding antibody serves as the targeting vehicle for a therapeutic radionuclide payload. The collaboration also encompasses potential bispecific antibody formats, given Regeneron's established expertise in that area. Regeneron noted in its public commentary that it intends to explore these agents as monotherapy and in rational combination with its immunotherapy platform, citing lung cancer as one area of interest where its PD-1 inhibitor is already in use. The specific antigens, antibody names, and radionuclide payloads for the collaboration programs have not been publicly identified. The theranostic component of the agreement, pairing matched diagnostic and therapeutic agents using the same antibody targeting vector, supports patient stratification and dosimetry assessment ahead of and during treatment. Telix will lead commercialization of the diagnostic assets developed under the collaboration. Strategic implications. Regeneron's entry into radiopharmaceutical oncology drug development marks a modality expansion for a company whose oncology portfolio has been anchored in antibody-based immunotherapy. The company indicated it views targeted radiopharmaceuticals as a frontier in oncology and has framed the collaboration as an opportunity to apply its antibody discovery engine to a delivery modality it has not previously pursued commercially. For Telix, the arrangement provides validation of its radiopharmaceutical manufacturing infrastructure as a platform asset capable of attracting large-scale co-development partnerships. Telix's existing commercial radiopharmaceutical portfolio includes Illuccix kit for the preparation of Ga-68 Glu-urea-Lys(ahx)-hbed-CC injection (also known as 68Ga-PSMA-11 injection), approved by the US FDA as a prostate cancer imaging agent. In addition, the firm announced on April 9, 2026, that the US FDA has accepted an NDA filing for TLX101-Px (Pixclara, Floretyrosine F 18 or 18F-FET), an investigational PET agent for the imaging of glioma (brain cancer). Your email address will not be published. Required fields are marked *

GlobalData
Apr 13th, 2026
Telix and Regeneron to co-develop radiopharmaceutical therapies.

Telix and Regeneron to co-develop radiopharmaceutical therapies. The partnership reflects a focus on precision oncology, seeking to enhance patient selection and assess treatment responses. Telix and Regeneron Pharmaceuticals have entered a partnership for the development and commercialisation of new radiopharmaceutical therapies. This collaboration aims to integrate Telix's expertise in radiopharmaceutical platforms, global manufacturing and supply chain infrastructure with Regeneron's biologics knowledge, particularly in bispecific antibody discovery. Regeneron will initially provide Telix with an upfront cash payment of $40m for access to the latter's radiopharmaceutical manufacturing platform for four therapeutic initiatives. There is an option for Regeneron to expand to another four programmes, which would involve further upfront payments. Both companies will equally share the costs and potential profits worldwide, with Telix optionally co-promoting certain products. If Telix chooses to step back from funding a specific programme, it could gain up to $535m in developmental and commercial milestones, in addition to low double-digit royalties on subsequent net sales. Regeneron oncology and antibody technology research senior vice-president John Lin said: "At Regeneron, Pharmaceutical Technology follow the science to determine the best therapeutic approach for each disease, continuously expanding its toolbox of treatment modalities - from monoclonal and bispecific antibodies to cell therapies and beyond. "Targeted radiopharmaceuticals represent a rapidly emerging frontier in oncology and an exciting opportunity to bring new treatment options to patients in need." The collaboration will include several solid tumour targets from Regeneron's antibody portfolio, benefiting from its VelocImmune mice technology. It reflects a joint focus on precision oncology, seeking to enhance patient selection and assess treatment responses through new radio-diagnostics. The companies also plan to develop diagnostic assets, where Telix will spearhead the commercialisation efforts, and Regeneron will receive a predetermined share of the profits. In December 2025, Regeneron teamed up with Tessera Therapeutics to develop and commercialise Tessera's rare disease in vivo gene writing programme, TSRA-196. Give your business an edge with its leading industry insights.

Yahoo Finance
Apr 13th, 2026
Dupixent approved in EU as first targeted medicine for chronic spontaneous urticaria in children aged 2-11

Regeneron Pharmaceuticals and Sanofi announced that the European Commission has approved Dupixent (dupilumab) for treating moderate-to-severe chronic spontaneous urticaria in children aged 2 to 11 years. The approval applies to patients with inadequate response to histamine-1 antihistamines who are naïve to anti-immunoglobulin E therapy. This expands Dupixent's existing EU approval for CSU, which previously covered adults and adolescents aged 12 and older. The drug is now approved for children under 12 across four chronic diseases driven partly by type 2 inflammation. The approval is based on data from the LIBERTY-CUPID clinical trial programme, including efficacy data extrapolated from two Phase 3 adult trials and pharmacokinetic, safety and efficacy data from the CUPIDKids Phase 3 trial in children aged 2 to 11.

The Associated Press
Apr 13th, 2026
EU approves Sanofi and Regeneron's Dupixent as first targeted medicine for young children with chronic urticaria

The European Commission has approved Dupixent (dupilumab) for treating moderate-to-severe chronic spontaneous urticaria in children aged two to 11 years with inadequate response to antihistamines. Developed by Sanofi and Regeneron, this marks the first targeted medicine for young children with the condition in the EU. The approval, based on the LIBERTY-CUPID clinical study programme, expands Dupixent's CSU indication to children as young as two years. The drug is now approved for children under 12 across four chronic diseases driven partly by type 2 inflammation. Clinical studies showed Dupixent significantly reduced urticaria activity, including itch and hives, compared with placebo at Week 24. Safety results were consistent with Dupixent's known profile in dermatological indications. A supplemental biologics licence application is under review in the US for the same patient population.

INACTIVE